SPRO
Price
$2.94
Change
+$0.04 (+1.38%)
Updated
Jun 27 closing price
Capitalization
164.38M
38 days until earnings call
XENE
Price
$32.40
Change
+$0.20 (+0.62%)
Updated
Jun 27 closing price
Capitalization
2.49B
38 days until earnings call
Interact to see
Advertisement

SPRO vs XENE

Header iconSPRO vs XENE Comparison
Open Charts SPRO vs XENEBanner chart's image
Spero Therapeutics
Price$2.94
Change+$0.04 (+1.38%)
Volume$1.69M
Capitalization164.38M
Xenon Pharmaceuticals
Price$32.40
Change+$0.20 (+0.62%)
Volume$13.15M
Capitalization2.49B
SPRO vs XENE Comparison Chart in %
Loading...
SPRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SPRO vs. XENE commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SPRO is a Buy and XENE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (SPRO: $2.94 vs. XENE: $32.40)
Brand notoriety: SPRO and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SPRO: 30% vs. XENE: 964%
Market capitalization -- SPRO: $164.38M vs. XENE: $2.49B
SPRO [@Biotechnology] is valued at $164.38M. XENE’s [@Biotechnology] market capitalization is $2.49B. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SPRO’s FA Score shows that 1 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • SPRO’s FA Score: 1 green, 4 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, both SPRO and XENE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SPRO’s TA Score shows that 5 TA indicator(s) are bullish while XENE’s TA Score has 3 bullish TA indicator(s).

  • SPRO’s TA Score: 5 bullish, 4 bearish.
  • XENE’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, SPRO is a better buy in the short-term than XENE.

Price Growth

SPRO (@Biotechnology) experienced а -2.65% price change this week, while XENE (@Biotechnology) price change was +1.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

SPRO is expected to report earnings on Aug 07, 2025.

XENE is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($2.49B) has a higher market cap than SPRO($164M). SPRO YTD gains are higher at: 185.437 vs. XENE (-17.347). SPRO has higher annual earnings (EBITDA): -73.06M vs. XENE (-290.36M). XENE has more cash in the bank: 550M vs. SPRO (48.9M). SPRO has less debt than XENE: SPRO (3.96M) vs XENE (8.68M). SPRO has higher revenues than XENE: SPRO (28.3M) vs XENE (7.5M).
SPROXENESPRO / XENE
Capitalization164M2.49B7%
EBITDA-73.06M-290.36M25%
Gain YTD185.437-17.347-1,069%
P/E Ratio10.75N/A-
Revenue28.3M7.5M377%
Total Cash48.9M550M9%
Total Debt3.96M8.68M46%
FUNDAMENTALS RATINGS
SPRO vs XENE: Fundamental Ratings
SPRO
XENE
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
76
Overvalued
PROFIT vs RISK RATING
1..100
10045
SMR RATING
1..100
9895
PRICE GROWTH RATING
1..100
3457
P/E GROWTH RATING
1..100
54
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SPRO's Valuation (59) in the Pharmaceuticals Major industry is in the same range as XENE (76) in the Biotechnology industry. This means that SPRO’s stock grew similarly to XENE’s over the last 12 months.

XENE's Profit vs Risk Rating (45) in the Biotechnology industry is somewhat better than the same rating for SPRO (100) in the Pharmaceuticals Major industry. This means that XENE’s stock grew somewhat faster than SPRO’s over the last 12 months.

XENE's SMR Rating (95) in the Biotechnology industry is in the same range as SPRO (98) in the Pharmaceuticals Major industry. This means that XENE’s stock grew similarly to SPRO’s over the last 12 months.

SPRO's Price Growth Rating (34) in the Pharmaceuticals Major industry is in the same range as XENE (57) in the Biotechnology industry. This means that SPRO’s stock grew similarly to XENE’s over the last 12 months.

XENE's P/E Growth Rating (4) in the Biotechnology industry is in the same range as SPRO (5) in the Pharmaceuticals Major industry. This means that XENE’s stock grew similarly to SPRO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SPROXENE
RSI
ODDS (%)
Bearish Trend 4 days ago
76%
Bullish Trend 4 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
81%
Bearish Trend 4 days ago
85%
Momentum
ODDS (%)
N/A
Bearish Trend 4 days ago
77%
MACD
ODDS (%)
Bearish Trend 4 days ago
85%
Bullish Trend 4 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
89%
Bullish Trend 4 days ago
74%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
74%
Advances
ODDS (%)
Bullish Trend 11 days ago
71%
Bullish Trend 4 days ago
72%
Declines
ODDS (%)
N/A
Bearish Trend 14 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 4 days ago
80%
Bearish Trend 4 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
SPRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MLNSX26.070.21
+0.81%
Morgan Stanley Instl Glbl Concntr R6
GGCPX15.140.11
+0.73%
Goldman Sachs International T/M Eq P
CRMSX12.950.08
+0.62%
CRM Small Cap Value Inv
VEXPX113.310.29
+0.26%
Vanguard Explorer Inv
GSBUX26.690.02
+0.07%
Goldman Sachs Income Builder R6

SPRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRO has been loosely correlated with ASBP. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRO jumps, then ASBP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRO
1D Price
Change %
SPRO100%
+1.38%
ASBP - SPRO
62%
Loosely correlated
-7.03%
CLGN - SPRO
43%
Loosely correlated
+0.36%
ITOS - SPRO
35%
Loosely correlated
-0.60%
XENE - SPRO
32%
Poorly correlated
+0.62%
SYRE - SPRO
31%
Poorly correlated
-4.99%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with IDYA. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
+0.62%
IDYA - XENE
56%
Loosely correlated
-4.13%
CRNX - XENE
54%
Loosely correlated
-0.10%
ATXS - XENE
54%
Loosely correlated
N/A
DNLI - XENE
51%
Loosely correlated
-2.69%
IMVT - XENE
50%
Loosely correlated
-1.77%
More